ArticleMolecular cancer research : MCR2026
ERG Orchestrates a Dedifferentiation-Senescence-Inflammation Triad in Prostate Cancer.
Article in Molecular cancer research : MCR, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
22 authors.
Funding
Abstract
ERG fusions occur in about 50% of prostate cancers and represent early somatic events that co-initiate tumorigenesis. Yet, the molecular programs unleashed by ERG at disease onset remain elusive. In this study, the inducible, temporally controlled expression of ERG enabled the accurate mapping of early ERG-driven processes associated with an apparent decrease in cell fitness across a panel of prostate cells. We observed that ERG triggers senescence and epithelial-mesenchymal transition (EMT), generating distinct cellular states in which EMT and senescence coexist in the same cell or occur independently. ERG-mediated activation of canonical and noncanonical TGFβ signaling differentially regulates EMT and senescence markers. Moreover, ERG drives context-dependent changes in cell identity and promotes an intermediate basal-luminal cell population with stem cell gene expression. Notably, p53 loss enhances ERG-driven expression of cell plasticity markers without affecting senescence. Transcriptomic investigation of ERG-expressing epithelial cells revealed activation of inflammatory signals. Conditioned medium experiments demonstrated paracrine-mediated inflammation in epithelial ERG-negative, stromal, and myeloid cells. Consistently, patient-derived expression data from five independent cohorts and 2,048 men showed activation of TNFA-NFKB and TGFβ signaling in ERG-rearranged tumors. Furthermore, deconvolution analysis indicated a higher infiltration of inflammatory macrophages in ERG-positive tumors. Altogether, we uncovered a previously unrecognized triad of ERG-driven processes-dedifferentiation, senescence, and inflammation-that may underpin its oncogenic potential and shape prostate cancer initiation and therapeutic response. IMPLICATIONS: Temporal control of ERG expression in prostate cells enabled accurate mapping of ERG-driven processes, identifying dedifferentiation, senescence, and inflammation as candidate contributors to ERG-dependent tumorigenesis and therapeutic response.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.